‘Garbage in, garbage out’ is a well-known principle in the machine learning (ML) community, and it is certainly true when it comes to adopting ML-based methods in biotech and drug discovery ..read more

From gene editing and artificial intelligence (AI)-driven protein design, to cutting-edge 3D bioprinting, tissue engineering and microfluidics – Lithuania appears to be a home for a vibrant  ecosystem of companies bridging deeptech and biology research. According to Invest Lithuania, a government-owned non-profit agency, the country is home to more than 600 life science companies, including large R&D centers of some global enterprises like Thermo Fisher Scientific and Teva ..read more

In the dynamic field of life sciences, both biological research and AI are coming together to alter our perspective on life at its most basic level. Dr. Markus Gershater, Co-founder and Chief Science Officer of Synthace, sheds light on the challenges and opportunities this union presents. Synthace, a UK-based no-code platform, allows for the design and execution of experiments, subsequently producing and analyzing structured data. With AI's potential to revolutionize our approach to biological systems, it also highlights the need for a change in our scientific methods and thinking. As past tec ..read more

Biotechnology is more than just an emerging scientific frontier, it also impacts global economy, competition, and societal transformation. To learn about a more expanded context of biotech innovations in the US economy, geopolitics, and society, I asked several questions to Abigail Kukura, the Director of Future Technology Platforms at the Special Competitive Studies Project (SCSP).  Founded Dr. Eric Schmidt, former CEO of Google, SCSP is a non-partisan, non-profit initiative with a clear mission: to make recommendations to strengthen America’s long-term competitiveness as artificial inte ..read more

In August, AbbVie has secured European Commission (EC) approval for AQUIPTA® (atogepant) as a preventive treatment for adults experiencing four or more migraine days per month, making it the European Union's first and only daily oral CGRP receptor antagonist treatment for both chronic and episodic migraines. Dr. Michael Seminerio, Therapeutic Area Lead and Senior Global Medical Affairs Director for AbbVie’s migraine portfolio, agreed to explain a bit more about this approval and provide some background context for the clinical data, safety and the impact this news can have on the migrane ..read more

The UK’s health technology market has seen unprecedented levels of M&A transactions and fundraising. The Covid-19 pandemic acted as a catalyst, accelerating the adoption of digital health solutions, and sparking interest amongst investors to get involved in the sector ..read more

Clinical trials are the lifeline of modern medicine, bridging the gap between lab-borne scientific discoveries and the availability of life-saving treatments for patients. Unfortunately, the success rate of clinical trials, particularly in the field of oncology, is not as robust as one might hope. In fact, a 2019 study of 7,455 interventional phase trials in oncology conducted from 2000 to 2015 suggests an estimate that only 3.4% of cancer drugs that enter Phase I clinical trials ultimately receive FDA approval. Many of these failures can be attributed to obstacles such as poor trial design an ..read more

The sphere of oncology continues to grapple with the complex nature of brain and central nervous system (CNS) tumors. Data predicts that in 2023, the United States will witness approximately 24,810 adults and 5,230 children diagnosed with primary brain or spinal cord tumors. When viewed on a global scale, the figures from 2020 reveal that over 308,000 individuals confronted the reality of such primary tumors. Notwithstanding the advancements in therapeutic strategies, the fatality rate associated with brain and other nervous system cancers persistently occupy the tenth position in the list of ..read more

With over half of the world's population being female, it's only natural that the world of femtech is experiencing a tremendous surge of interest. The numbers speak volumes. A recent research report by Global Market Insights predicts that the femtech market will soar beyond $48.5 billion by 2025. This exciting growth is fueled by the innovative integration of cutting-edge technologies such as tracking wearables, artificial intelligence (AI), intuitive apps, and noninvasive hardware, all aimed at revolutionizing female health and well-being ..read more

Navigating the dynamic intersection of biology and data science, Eduardo Abeliuk, the CEO of TeselaGen Biotechnology, invites us on a journey through his career and his company's role in the biotechnology industry. Abeliuk's roots in computational biology research at Stanford University and his rich background as a founder, advisor, board member, and investor have collectively sculpted the robust ethos of TeselaGen. Amid an era of growth, Abeliuk discusses the profound influences of artificial intelligence and machine learning on biotechnology and outlines a future of intercompany collaboratio ..read more